Cedrik Britten
Company: Immatics
Job title: Chief Medical Officer
Seminars:
Clinical Activity of IMA203 TCR-T Targeting PRAME in Melanoma & Beyond 9:30 am
Characterising cancer testis antigen PRAME as a target for TCR-based therapies Providing a clinical update on IMA203 TCR-T demonstrating a manageable tolerability profile as well as deep and durable responses in heavily pre-treated last-line melanoma patients Discussing clinical activity of 2nd generation TCR-T IMA203CD8 in solid cancer patientsRead more
day: Conference Day 2 - AM